8 results about "Neuroblastoma cell" patented technology

The invention relates to the technical field of biomedicine, in particular to a novel target spot for resisting chikungunya virus infection and application. According to the invention, human neuroblastoma cells (SH-SY5Y) and human brain astroblastoma cells (U87) are taken as target cells, and the expression of the target cell part capable of exerting receptor action membrane protein is down-regulated by adopting an RNA interference technology, so that a host factor capable of effectively inhibiting CHIKV infection of human nerve cells is found, and the purpose of blocking CHIKV infection from the source is achieved. It is found that platelet membrane glycoprotein VI (GP6) plays an important role in CHIKV infection SH-SY5Y and U87 cells, expression of GP6 is reduced, and CHIKV infection can be obviously inhibited. The invention provides an application of GP6 in preparation of a medicine for preventing or treating chikungunya virus infection, and provides a new target spot and a treatment scheme for clinically preventing and treating fever, arthralgia, joint swelling, muscle pain, headache, nausea, fatigue, rash and other diseases caused by CHIKV infection.

The invention discloses a method for stereoselectively synthesizing a chiral triarylmethane thioether compound with antitumor biological activity, and relates to the technical field of medicine synthesis. According to the invention, a seven-membered ring system 3-indolyl [1, 4] sulfur azacycloheptane compound is used as a raw material, an asymmetric Friedel-Crafts alkylation reaction with nucleophilic indole is realized through a new strategy that a spiro chiral phosphonic acid catalyst catalyzes bond breaking of a carbon-nitrogen bond, a high-quality path is provided for synthesis of a chiral triarylmethane thioether compound, and the chiral triarylmethane thioether compound has a wide application prospect. Meanwhile, the reaction has the characteristics of easily available raw materials and mild conditions, and also has the technical advantages of high enantioselectivity and high atom economy. The chiral triarylmethane thioether compound provided by the invention has an obvious inhibition effect on the growth of human cervical cancer cells (HeLa), pancreatic cancer cells (Panc-1) and human bone marrow neuroblastoma cells (Sy5Y), shows good anti-tumor biological activity, and has important positive significance for promoting the research and development of anti-tumor drugs.

The invention discloses application of MBD3 as an intervention target in preparation of a neuroblastoma treatment medicine, and belongs to the technical field of biological medicine. According to the application disclosed by the invention, a substance for reducing the expression level of the MBD3 gene or reducing the protein level of the MBD3 is applied to the development of a medicine for treating the neuroblastoma, and it is proved that interference on the expression of the MBD3 gene can induce the G0 / G1 phase cell cycle arrest of neuroblastoma cells and promote cell apoptosis, so that the in-vivo and in-vitro proliferation activity of the neuroblastoma cells is effectively inhibited; the small-molecule drug enbopiravidone can down-regulate the MBD3 protein level and significantly inhibit the growth of neuroblastoma cells. According to the invention, MBD3 is taken as a new target spot for treating neuroblastoma, a new direction is provided for overcoming the limitation of the existing therapy, a scientific basis is provided for developing a novel neuroblastoma treatment strategy based on MBD3 inhibition, and the application has important significance for improving the living quality and survival prognosis of high-risk children.

The application discloses a tetrazole derivative, which has a structure shown in a general formula I. The application also discloses a composition containing the tetrazole derivative and application of the tetrazole derivative in preparation of a drug for preventing and resisting stroke. The inventors of the application have confirmed through multiple experiments that the compound has obvious inhibiting effect on ADP-induced platelet aggregation activity, outstanding damage protection effect on OGD / R fetal rat primary cortical neuron cells and neuron-like cells induced and differentiated from neuroblastoma cells (N2A), good anti-stroke efficacy on an animal model of focal cerebral ischemia constructed by a line plug method for temporarily blocking a middle cerebral artery and good rat oral pharmacokinetic properties. Therefore, the compound can be applied to a drug for treating and preventing stroke as a neuroprotective agent.

The invention relates to the technical field of biomedicine, in particular to a novel target spot for resisting chikungunya virus infection and application. According to the invention, human neuroblastoma cells (SH-SY5Y) and human brain astroblastoma cells (U87) are taken as target cells, and the expression of the target cell part capable of exerting receptor action membrane protein is down-regulated by adopting an RNA interference technology, so that a host factor capable of effectively inhibiting CHIKV infection of human nerve cells is found, and the purpose of blocking CHIKV infection from the source is achieved. The invention discovers that the nerve cilia protein 2 (NRP2) plays an important role in CHIKV infection SH-SY5Y and U87 cells, and the CHIKV infection can be obviously inhibited by down-regulating the expression of the NRP2. The invention provides an application of NRP2 in preparation of a medicine for preventing or treating chikungunya virus infection, and provides a new target spot and a treatment scheme for clinically preventing and treating fever, arthralgia, arthrocele, muscular pain, headache, nausea, fatigue, rash and other diseases caused by CHIKV infection.

The application belongs to the technical field of biological medicine, and particularly relates to an immune liposome targeting ganglioside GD2 and mitochondria as well as a preparation method and application thereof. The application couples LX3 and thiolated daratumumab to DSPE-PEG2000 respectively to obtain DSPE-PEG2000-LX3 and DSPE-PEG2000-aGD2, and then is compounded with DSPC and cholesterol to obtain the immune liposome, which has good dispersity, excellent stability and cannot induce cytotoxicity. Cell combination and uptake analysis shows that the immune liposome can specifically target ganglioside GD2 positive tumor cells and then further reach mitochondria thereof. Compared with existing liposomes, the immune liposome provided by the application has double targeting functions of ganglioside GD2 and mitochondria, and can selectively deliver an anti-tumor drug into mitochondria of neuroblastoma cells.

This invention discloses the preparation method and uses of scutellarin 7-phosphate derivatives; belonging to the field of natural medicines and medicinal chemistry. The scutellarin 7-phosphate derivatives and their pharmaceutically acceptable salt structures described in this invention are shown in the following general formula I: By introducing a phosphate group at the 7-position, the scutellarin 7-phosphate derivatives are used in the preparation of drugs for cerebrovascular diseases. They exhibit excellent neuroprotective effects. The scutellarin phosphate derivatives of this invention have good protective activity against H2O2-induced oxidative damage to human neuroblastoma SH-SY5Y cells. Furthermore, the neuroprotective effects of some compounds are significantly stronger than those of the lead compound scutellarin.

The application relates to the field of tumor treatment drugs and discloses application of P5A ATPase as a target in preparation of a neuroblastoma treatment drug. It is found for the first time that P5A ATPase can affect the expression level of LRP8 protein and endoplasmic reticulum translocation of LRP8 signal peptide guided peptide chains, and further affect the growth and proliferation of neuroblastoma cells, so that a new target is provided for development of a neuroblastoma treatment drug. In addition, it is found that two P5A ATPase inhibitors, sodium metavanadate and DCC, can inhibit the endoplasmic reticulum translocation of LRP8 signal peptide guided peptide chains, reduce the expression level of LRP8 protein, and further inhibit the growth and proliferation of neuroblastoma cells, so that a new treatment drug for neuroblastoma is provided.